Inactive Instrument

WNTH AB Stock Swiss Exchange

Equities

WNT

SE0003553130

Biotechnology & Medical Research

End-of-day quote Swiss Exchange
- SEK - Intraday chart for WNTH AB
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 - Sales 2023 - Capitalization 36.89M 395M 50.23M
Net income 2022 -30M -321M -40.85M Net income 2023 -32M -342M -43.58M EV / Sales 2022 -
Net cash position 2022 9.92M 106M 13.51M Net cash position 2023 26.88M 288M 36.61M EV / Sales 2023 -
P/E ratio 2022
-1.24 x
P/E ratio 2023
-0.87 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 15.12%
More Fundamentals * Assessed data
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
WntResearch Initiates Collaboration with Business Sweden with the Goal of Establishing Commercial Partnerships for Foxy-5 in Japan and South Korea CI
WntResearch AB Continues to the Next Step in the Phase 2 Study Neofox with the Highest Evaluated Dose of Foxy-5 CI
WntResearch Announces CEO Changes CI
WntResearch Continues to the Second Dose Group in Clinical Proof of Concept Study of Foxy-5 CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
WntResearch AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Certain Shares of WntResearch AB are subject to a Lock-Up Agreement Ending on 16-JUL-2023. CI
WntResearch AB Announces New Study Plan Approves for Wnt Research's Phase II Study CI
WntResearch AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
WntResearch AB Reports Earnings Results for the Full Year Ended December 31, 2022 CI
WntResearch AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022 CI
WntResearch AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
More news
Managers TitleAgeSince
Chief Executive Officer 54 01-09
Founder 68 07-09-23
Director of Finance/CFO - 20-09-10
Members of the board TitleAgeSince
Director/Board Member 72 15-06-08
Founder 68 07-09-23
Chairman 62 21-12-31
More insiders
WntResearch AB is a Sweden-based company engaged in the translational cancer research. Its aim is to develop anti-metastatic therapies based on an increased understanding of the mechanisms underlying the metastatic process and the evaluation of specific small molecules that can specifically interact with this process. The Company’s programs focus on the role of the Wnt-5a protein in the metastatic process. As of December 31, 2011, the Company had two projects, namely Foxy-5 and Box-5. Foxy-5 is a hexapeptide mimicking the effects of WNT-5a. Box-5 is a peptide antagonizing the effects of Wnt-5a. As of March 31, 2012, the Company’s largest shareholder was Forskarpatent I Syd AB, which held 26.55% shares.
Calendar
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW